Response to letter to the Editors-Safety of long-term denosumab therapy
Support Care Cancer
.
2017 Feb;25(2):353-355.
doi: 10.1007/s00520-016-3492-8.
Epub 2016 Nov 24.
Authors
Alison T Stopeck
1
,
Douglas J Warner
2
Affiliations
1
Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, 11794-8151, USA. Alison.Stopeck@stonybrookmedicine.edu.
2
Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA. djwarner@amgen.com.
PMID:
27885467
PMCID:
PMC5196008
DOI:
10.1007/s00520-016-3492-8
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Bone Density
Bone Density Conservation Agents*
Denosumab*
Humans
Substances
Bone Density Conservation Agents
Denosumab